Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Insulet Corp
(NQ:
PODD
)
202.77
-2.38 (-1.16%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Insulet Corp
< Previous
1
2
3
4
5
6
7
Next >
33 Stocks Moving In Friday's Mid-Day Session
January 28, 2022
Gainers Imperial Petroleum Inc. (NASDAQ: IMPP) shares jumped 126% to $2.6219. Imperial Petroleum, last month, posted Q3 revenue of $4.1 million. Yoshitsu Co., Ltd (NASDAQ: TKLF...
Via
Benzinga
Benzinga Pro's Top 5 Stocks To Watch For Friday, Jan. 28, 2022: PODD, KR, TEAM, GOOGL, SBUX
January 28, 2022
Today's 5 Stock Ideas: Insulet (PODD) - Shares up premarket. The company announced FDA clearance of its Omnipod 5 Automated Insulin Delivery System. Kroger (KR) - Shares...
Via
Benzinga
If You Invested $100 In This Stock 5 Years Ago, Here's How Much You Would Have Today
January 13, 2022
Insulet (NASDAQ:PODD) has outperformed the market over the past 5 years by 24.86% on an annualized basis. Buying $100 In PODD: 5 years ago, an investor could have purchased 2.30...
Via
Benzinga
This Foreboding Sign Looms Over Insulet's Chart
January 13, 2022
If history is any guide, there may be trouble ahead for shares of Insulet (NASDAQ:PODD). A so-called "death cross" has formed on its chart and, not surprisingly, this could be...
Via
Benzinga
Earnings Scheduled For May 6, 2021
May 06, 2021
Companies Reporting Before The Bell • ViacomCBS (NASDAQ:VIAC) is projected to report quarterly earnings at $1.22 per share on revenue of $7.30 billion. • Cohen...
Via
Benzinga
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge
May 01, 2021
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name...
Via
Benzinga
Exposures
Product Safety
10 Biggest Price Target Changes For Monday
November 08, 2021
Barclays cut Deciphera Pharmaceuticals, Inc. (NASDAQ:
Via
Benzinga
10 Biggest Price Target Changes For Friday
November 05, 2021
Wedbush raised Uber Technologies, Inc. (NYSE:UBER)...
Via
Benzinga
Insulet Corporation (PODD) Q3 2021 Earnings Call Transcript
November 04, 2021
PODD earnings call for the period ending September 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Insulet Posts Mixed Third Quarter, But Raises Sales Guide On Narrow Beat
November 04, 2021
Insulet raised its full-year sales outlook Thursday on its third-quarter sales beat.
Via
Investor's Business Daily
Insulet's Insulin Delivery System Shows Durable Glycemic Control With One Year of Use
September 30, 2021
Insulet Corporation (NASDAQ: PODD) presented data from the pivotal trial extension phase of the Omnipod 5 Automated Insulin Delivery System. Omnipod 5 is a...
Via
Benzinga
The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO
November 04, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral COVID-19 Pill Authorized In UK Merck &...
Via
Benzinga
Exposures
COVID-19
5 Top Stocks for September
September 11, 2021
Our analysts give you five picks you can add to your portfolio today.
Via
The Motley Fool
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
October 31, 2021
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc...
Via
Benzinga
The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi's Pemphigus Trial Disappointment, Humanigen's COVID-19 Drug Denied Emergency Use Authorization
September 09, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 8) Abbott Laboratories (NYSE:...
Via
Benzinga
Exposures
COVID-19
Looking into Insulet's Return on Capital Employed
August 23, 2021
After pulling data from Benzinga Pro it seems like during Q2, Insulet (NASDAQ:PODD) earned $26.30 million, a 61.35% increase from the preceding quarter. Insulet also posted a...
Via
Benzinga
The Daily Biotech Pulse: MacroGenics' Clinical Trial Disappointment, Sanofi to Buy Kadmon, Alector Loses 2 Key Executives, ADMA's FDA Nod
September 08, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 7) Adial Pharmaceuticals, Inc...
Via
Benzinga
Exposures
Product Safety
FDA Clears Use Of Eli Lilly's Insulin With Insulet's Infusion Pumps
August 16, 2021
The
Via
Benzinga
Exposures
Product Safety
Insulet Stock Dives On Unexpected Delay For Next-Generation Insulin Pump
August 06, 2021
Insulet said Thursday it expects a one-quarter delay for its next-generation insulin pump, leading PODD stock to tumble on Friday.
Via
Investor's Business Daily
Insulet Corporation (PODD) Q2 2021 Earnings Call Transcript
August 06, 2021
PODD earnings call for the period ending June 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
3 Stocks to Buy That Should Get a Boost From Pandemic-Driven Consumer Weight Gain
July 31, 2021
Athletic-apparel maker Lululemon and two diabetes specialists are poised to get a long-term tailwind from the COVID-19 pandemic.
Via
The Motley Fool
Exposures
COVID-19
Insulet Corp (PODD) Q1 2021 Earnings Call Transcript
May 07, 2021
PODD earnings call for the period ending March 31, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Benzinga's Top Ratings Upgrades, Downgrades For May 25, 2021
May 25, 2021
Upgrades For Appian Corp (NASDAQ:APPN), Macquarie upgraded the previous rating of Underperform to Neutral. For the first quarter, Appian had an EPS of $0.06, compared to...
Via
Benzinga
The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom
May 06, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 5) AbbVie Inc. (NYSE: ABBV)...
Via
Benzinga
Exposures
Product Safety
The Daily Biotech Pulse: Hyperphosphatemia Drug Regulatory Review Extended, Phathom Pharma Data Readout, 2 IPOs
April 30, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 29) AtriCure, Inc. (NASDAQ:...
Via
Benzinga
The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx
April 29, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 28) Axonics, Inc. (NASDAQ:...
Via
Benzinga
The Daily Biotech Pulse: FDA Rejection For Protalix, Amgen Q1 Trail Estimates, Pfizer Goes Shopping
April 28, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 27) Aldeyra Therapeutics, Inc...
Via
Benzinga
Exposures
Product Safety
The Daily Biotech Pulse: Lilly, Novartis Trail Q1 Estimates, Exec Departure At Applied Genetics, Patent Award For Scholar Rock, Aldeyra Data Readout
April 27, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 26) 10x Genomics, Inc. (NASDAQ...
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.